Full Press Release Details
argenx announces publication of efgartigimod Phase 2 primary immune thrombocytopenia trial results in American Journal of Hematology.
ARGX
argenx announces publication of efgartigimod Phase 2 primary immune thrombocytopenia trial results in American Journal of Hematology
Key Takeaway: argenx announces publication of efgartigimod Phase 2 primary immune thrombocytopenia trial results in American Journal of Hematology
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+36%
120-day peak, hindsight
Typical move
4.7%
average across 12 past catalysts
Lead asset
Empasiprubart
Phase 2 · AChR-Ab Seropositive Generalized Myasthenia Gravis